Compare VISN & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VISN | KARD |
|---|---|---|
| Founded | 1976 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2013 | 2026 |
| Metric | VISN | KARD |
|---|---|---|
| Price | $3.84 | $11.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.67 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 7.1M | 441.3K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 412.50% | N/A |
| EPS Growth | ★ 641.01 | N/A |
| EPS | ★ 29.48 | N/A |
| Revenue | ★ $1,931,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.89 | $12.23 |
| 52 Week High | $19.91 | $27.00 |
| Indicator | VISN | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 25.48 | 35.74 |
| Support Level | N/A | N/A |
| Resistance Level | $6.76 | $16.26 |
| Average True Range (ATR) | 0.25 | 1.30 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 1.79 | 0.60 |
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.